A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Epidermal growth factor receptor (EGFR) is a key target for non-small-cell lung cancer (NSCLC) therapeutics.
• Target-based drug development requires efficient screening methods for identifying inhibitors.

Purpose of the Study:

• To establish a high-throughput cell-based assay for screening EGFR inhibitors.
• To identify compounds that inhibit EGFR activation and downstream signaling pathways.

Main Methods:

• Development of a 32D cell line stably expressing EGFR (32D-EGFR).
• Utilized a dual-stimulation system (EGF and IL-3) for primary and secondary screening.
• In vitro kinase assays and Western blot analysis to confirm EGFR inhibition.

Main Results:

• Screened 20,000 compounds, identifying 9 that selectively inhibited EGF-dependent proliferation.
• 3 of the 9 hits demonstrated direct inhibition of EGFR kinase activity.
• Confirmed inhibition of EGFR phosphorylation in EGFR-transfected H1299 cells.

Conclusions:

• The 32D-EGFR assay system is effective for identifying novel EGFR inhibitors.
• This platform facilitates the discovery of potential antitumor agents targeting the EGFR pathway.
• The identified compounds show promise for NSCLC targeted therapy.